Published in

Wiley, Diabetes, Obesity and Metabolism, 7(22), p. 1151-1156, 2020

DOI: 10.1111/dom.14017

Links

Tools

Export citation

Search in Google Scholar

Can the Cardiovascular Risk Reductions Observed with Empagliflozin in the EMPA‐REG OUTCOME Trial be Explained by Concomitant Changes Seen in Conventional Cardiovascular Risk Factor Levels?

Journal article published in 2020 by Ruth L. Coleman ORCID, Alastair M. Gray ORCID, Uli C. Broedl, David Fitchett ORCID, Jyothis T. George, Hans J. Woerle, Bernard Zinman ORCID, Rury R. Holman ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO